Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Controlled Clinical Trial of Iparomlimab and Tuvonralimab Injection (QL1706) Plus Lenvatinib and Chemotherapy as First-Line Treatment for Extrapulmonary Neuroendocrine Carcinoma

NCT07738159 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT07738159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07738159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Controlled Clinical Trial of Iparomlimab and Tuvonralimab Injection (QL1706) Plus Lenvatinib and Chemotherapy as First-Line Treatment for Extrapulmonary Neuroendocrine Carcinoma
Lead sponsor
West China Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
September 1, 2030
Enrollment
92 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy, extrapulmonary neuroendocrine carcinoma (ep-nec), lenvatinib, ql1706